Incyte Corporation is a biopharmaceutical entity dedicated to the discovery, development, and global commercialization of its proprietary therapeutic innovations. Its portfolio features established medications such as JAKAFI, prescribed for the treatment of myelofibrosis and polycythemia vera. Another key offering is PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor designed to target oncogenic drivers found in various liquid and solid tumor types.